Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04524689
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2020-08-20
Brief Title:
Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-squamous Non-small-cell Lung Cancer NSQ NSCLC |
Keywords: